|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.36/-2.03
|
企业价值
71.91M
|
资产负债 |
每股账面净值
1.22
|
现金流量 |
现金流量率
--
|
损益表 |
收益
15.53M
|
每股收益
0.22
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/04 16:18 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. |